Suchergebnisse - "Oluwole, Olalekan O"

PubPharm (65)

21

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma : phase 1 UNIVERSAL trial interim results

enthalten in: Nature medicine | 2023

von Mailankody, S. | Matous, J. | Chhabra, S. | +15

CommentIn: Nat Med. 2023 Feb;29(2):303-304. - PMID 36690813

22

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma

enthalten in: Haematologica | 2023

von Zurko, J. | Ramdial, J. | Shadman, M. | +39

23

Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma

enthalten in: Leukemia & lymphoma | 2022

von Oluwole, O. | Chen, J. | Chan, K. | +6

24

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

enthalten in: Journal of hematology & oncology | 2022

von Shah, B. | Ghobadi, A. | Oluwole, O. | +27

25

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

enthalten in: Journal of hematology & oncology | 2022

von Shah, B. | Ghobadi, A. | Oluwole, O. | +27

26

Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma : Results from the US Lymphoma CAR-T Consortium

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Jacobs, M. | Jain, M. | Gao, F. | +23

27

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas

enthalten in: Transplantation and cellular therapy | 2022

von Riedell, P. | Hwang, W. | Nastoupil, L. | +15

CommentIn: Transplant Cell Ther. 2022 Oct;28(10):621-622. - PMID 36202524

28

Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools : The Vanderbilt experience

enthalten in: British journal of haematology | 2022

von Dholaria, B. | Mehraban, N. | Baer, B. | +7

29

Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma : Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

enthalten in: Transplantation and cellular therapy | 2022

von Perales, M. | Anderson, L. | Jain, T. | +5

30

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma : the phase 2 ZUMA-12 trial

enthalten in: Nature medicine | 2022

von Neelapu, S. | Dickinson, M. | Munoz, J. | +14

CommentIn: Nat Rev Clin Oncol. 2022 May;19(5):283. - PMID 35361894